$XBIO
Xenetic Biosciences, Inc.

2022 Q3 Form 10-Q Financial Statement

#000168316822005567 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $414.3K $416.7K $389.0K
YoY Change 18.6% 44.89% 104.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $863.2K $1.026M $907.3K
YoY Change -8.66% 15.22% -2.44%
% of Gross Profit
Research & Development $398.8K $2.077M $1.101M
YoY Change -48.88% 296.05% 74.83%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.262M $3.104M $2.009M
YoY Change -26.85% 119.31% 28.76%
Operating Profit -$847.8K -$2.687M -$1.620M
YoY Change -38.39% 138.29%
Interest Expense $45.48K $15.97K $25.91K
YoY Change 62.25% -23.0% 29.55%
% of Operating Profit
Other Income/Expense, Net $43.77K $14.89K $200.00
YoY Change -1604.09% -29.01%
Pretax Income -$804.0K -$2.672M -$1.594M
YoY Change -40.48% 141.46% 18.05%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$804.0K -$2.672M -$1.594M
YoY Change -40.48% 141.46% 18.05%
Net Earnings / Revenue -194.09% -641.26% -409.68%
Basic Earnings Per Share -$0.06 -$0.19 -$0.12
Diluted Earnings Per Share -$0.06 -$0.19 -$118.6K
COMMON SHARES
Basic Shares Outstanding 14.32M shares 14.07M shares 13.44M shares
Diluted Shares Outstanding 14.32M shares 14.07M shares 13.44M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.85M $14.93M $16.16M
YoY Change -29.71% 60.83% 61.4%
Cash & Equivalents $13.85M $14.93M $16.16M
Short-Term Investments
Other Short-Term Assets $319.1K $448.7K $732.4K
YoY Change -63.67% -51.11% -28.9%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $14.17M $15.38M $16.89M
YoY Change -31.16% 50.76% 52.98%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00 $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.406M $1.092M $1.095M
YoY Change 99.57% 52.53% 49.97%
Total Long-Term Assets $1.406M $1.092M $1.095M
YoY Change 99.57% 52.53% 52.06%
TOTAL ASSETS
Total Short-Term Assets $14.17M $15.38M $16.89M
Total Long-Term Assets $1.406M $1.092M $1.095M
Total Assets $15.57M $16.47M $17.98M
YoY Change -26.84% 50.87% 52.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $202.8K $472.7K $280.7K
YoY Change -18.4% 54.94% 33.66%
Accrued Expenses $848.1K $806.5K $782.6K
YoY Change -2.86% 23.48% 32.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.051M $1.279M $1.063M
YoY Change -6.3% 33.5% 32.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.051M $1.279M $1.063M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.051M $1.279M $1.063M
YoY Change -6.3% 32.4% 29.67%
SHAREHOLDERS EQUITY
Retained Earnings -$187.6M -$186.8M
YoY Change
Common Stock $14.34K $14.34K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $5.281M $5.281M
YoY Change
Treasury Stock Shares
Shareholders Equity $14.52M $15.19M $16.92M
YoY Change
Total Liabilities & Shareholders Equity $15.57M $16.47M $17.98M
YoY Change -26.84% 50.87% 52.92%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$804.0K -$2.672M -$1.594M
YoY Change -40.48% 141.46% 18.05%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.079M -$728.9K -$2.088M
YoY Change 4.44% 0.4% 37.35%
INVESTING ACTIVITIES
Capital Expenditures -$500.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$500.0K
YoY Change
Cash From Investing Activities $0.00 -$500.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -1.079M -728.9K -2.088M
Cash From Investing Activities 0.000 -500.0K
Cash From Financing Activities 0.000
Net Change In Cash -1.079M -1.229M -2.088M
YoY Change -110.36% 69.27% 37.35%
FREE CASH FLOW
Cash From Operating Activities -$1.079M -$728.9K -$2.088M
Capital Expenditures -$500.0K
Free Cash Flow -$579.3K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37937
dei Entity Registrant Name
EntityRegistrantName
XENETIC BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-2952962
dei Entity Address Address Line1
EntityAddressAddressLine1
40 Speen Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 102
dei Entity Address City Or Town
EntityAddressCityOrTown
Framingham
dei Entity Central Index Key
EntityCentralIndexKey
0001534525
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q2 xbio Exercise Of Purchase Warrants Value
ExerciseOfPurchaseWarrantsValue
usd
xbio Exercise Of Purchase Warrants Value
ExerciseOfPurchaseWarrantsValue
usd
xbio Exercise Of Purchase Warrants Value
ExerciseOfPurchaseWarrantsValue
usd
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01701
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
778-7720
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14316596 shares
CY2022Q2 us-gaap Cash
Cash
14927440 usd
CY2021Q4 us-gaap Cash
Cash
18244030 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
448733 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
479399 usd
CY2022Q2 us-gaap Treasury Stock Value
TreasuryStockValue
5281180 usd
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
5281180 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
15188921 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
18394257 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
15376173 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
18723429 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1091931 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1091931 usd
CY2022Q2 us-gaap Assets
Assets
16468104 usd
CY2021Q4 us-gaap Assets
Assets
19815360 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
472699 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
362470 usd
CY2022Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
806484 usd
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1058633 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1279183 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1421103 usd
CY2022Q2 us-gaap Liabilities
Liabilities
1279183 usd
CY2021Q4 us-gaap Liabilities
Liabilities
1421103 usd
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14343587 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13466603 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14316596 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13439612 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
14342 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
13465 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
207012317 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
205952729 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-186813066 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-182547265 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
253734 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
253734 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16468104 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19815360 usd
CY2022Q2 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
416710 usd
CY2021Q2 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
287603 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
805703 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
478819 usd
CY2022Q2 us-gaap Revenues
Revenues
416710 usd
CY2021Q2 us-gaap Revenues
Revenues
287603 usd
us-gaap Revenues
Revenues
805703 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
us-gaap Revenues
Revenues
478819 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2077499 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
524550 usd
CY2022Q2 xbio Issuance Of Common Stock In Connection With Purchase Of Inprocess Research And Development
IssuanceOfCommonStockInConnectionWithPurchaseOfInprocessResearchAndDevelopment
805000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3178898 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1154279 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1026290 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
890704 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1933599 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1821282 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
3103789 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
1415254 usd
us-gaap Operating Expenses
OperatingExpenses
5112497 usd
us-gaap Operating Expenses
OperatingExpenses
2975561 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2687079 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1127651 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4306794 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2496742 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1076 usd
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
238 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-877 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1122 usd
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
15965 usd
CY2021Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
20735 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
41870 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
42997 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14889 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
20973 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
40993 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
44119 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2672190 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1106678 usd
us-gaap Net Income Loss
NetIncomeLoss
-4265801 usd
us-gaap Net Income Loss
NetIncomeLoss
-2452623 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14066573 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14066573 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8746692 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8746692 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13755046 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13755046 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8746479 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8746479 shares
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
16920241 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
135870 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2672190 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
15188921 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
18394257 usd
xbio Issuance Of Common Stock In Connection With Purchase Of Inprocess Research And Development
IssuanceOfCommonStockInConnectionWithPurchaseOfInprocessResearchAndDevelopment
805000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
255465 usd
us-gaap Net Income Loss
NetIncomeLoss
-4265801 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
15188921 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
10945863 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
109922 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1106678 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
9949107 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
12215524 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
186206 usd
us-gaap Net Income Loss
NetIncomeLoss
-2452623 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
9949107 usd
us-gaap Net Income Loss
NetIncomeLoss
-4265801 usd
us-gaap Net Income Loss
NetIncomeLoss
-2452623 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
1305000 usd
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
19087 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
17160 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
255465 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
186206 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-11579 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-1059 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-141920 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2200 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2816590 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2245998 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
500000 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
-0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-500000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3316590 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2245998 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18244030 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11527552 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14927440 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9281554 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
xbio Issuance Of Common Stock To Acquire Inprocess Research And Development
IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment
805000 usd
xbio Issuance Of Common Stock To Acquire Inprocess Research And Development
IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment
0 usd
xbio Issuance Of Common Stock From Cashless Exercise Of Purchase Warrants
IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants
2 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
135870 usd
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
109922 usd
xbio Issuance Of Common Stock From Cashless Exercise Of Purchase Warrants
IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants
1 usd
CY2022Q2 us-gaap Payments For Fees
PaymentsForFees
0 usd
us-gaap Payments For Fees
PaymentsForFees
0 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
300000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
200000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
255465 usd
us-gaap Share Based Compensation
ShareBasedCompensation
186206 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
300000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
200000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
32600000 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
31400000 usd
CY2022Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
19087 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
17160 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9611 usd
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
37408 usd
CY2022Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
0 usd
CY2021Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
7957 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9611 usd
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
37408 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7957 usd

Files In Submission

Name View Source Status
0001683168-22-005567-index-headers.html Edgar Link pending
0001683168-22-005567-index.html Edgar Link pending
0001683168-22-005567.txt Edgar Link pending
0001683168-22-005567-xbrl.zip Edgar Link pending
a1.jpg Edgar Link pending
a2.jpg Edgar Link pending
a3.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xbio-20220630.xsd Edgar Link pending
xenetic_ex1001.htm Edgar Link pending
xenetic_ex1002.htm Edgar Link pending
xenetic_ex1003.htm Edgar Link pending
xenetic_ex1004.htm Edgar Link pending
xenetic_ex3101.htm Edgar Link pending
xenetic_ex3102.htm Edgar Link pending
xenetic_ex3201.htm Edgar Link pending
xenetic_i10q-063022.htm Edgar Link pending
xbio-20220630_pre.xml Edgar Link unprocessable
xbio-20220630_lab.xml Edgar Link unprocessable
xbio-20220630_cal.xml Edgar Link unprocessable
xenetic_i10q-063022_htm.xml Edgar Link completed
xbio-20220630_def.xml Edgar Link unprocessable